All AbMole products are for research use only, cannot be used for human consumption.
TRV130 hydrochloride (Oliceridine) is a functionally selective μ-opioid receptor agonist developed by Trevena Inc. TRV130 elicits robust G protein signaling, but with far less β-arrestin 2 recruitment and receptor internalization, it displays less adverse effects.
Anesth Analg. 2018 Jul 21.
Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein[FIGURE DASH]Biased Ligand in Mice.
TRV130 hydrochloride purchased from AbMole
 |
Source | Anesthesia & Analgesia (2018 Jul). Figure 5. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
| Method | CPP assay | |
| Cell Lines | mice | |
| Concentrations | 1.25 or 10 mg/kg | |
| Incubation Time | 7 d | |
| Results | Figure 5 shows that TLR4 mRNA expression was increased in the lumbar spinal cord tissue of fracture mice that received morphine at 3 weeks after injury(P < .05), while no such changes were observed in the fracture mice by the administration of oliceridine (P> .05). |
 |
Source | Anesthesia & Analgesia (2018 Jul). Figure 4. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
| Method | CPP assay | |
| Cell Lines | mice | |
| Concentrations | 5 μL/injection | |
| Incubation Time | 7 d | |
| Results | The small amount of ethanol in the oliceridine vehicle (5 μL/injection) did not appear to affect nociceptive sensitivity as demonstrated in Figure 4. |
 |
Source | Anesthesia & Analgesia (2018 Jul). Figure 3. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
| Method | CPP assay | |
| Cell Lines | mice | |
| Concentrations | 1.25 or 10 mg/kg | |
| Incubation Time | 3 d | |
| Results | However, a dose of oliceridine providing similar levels of analgesia, 1.25 mg/kg, did not cause statistically significant CPP (P > .05). |
 |
Source | Anesthesia & Analgesia (2018 Jul). Figure 2. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
| Method | CPP assay | |
| Cell Lines | mice | |
| Concentrations | 1.25 or 10 mg/kg | |
| Incubation Time | 3 d | |
| Results | Figure 2 shows that both chronic oliceridine and morphine treatment reduced the mechanical paw withdraw thresholds in comparison with the baseline thresholds (P < .001). |
 |
Source | Anesthesia & Analgesia (2018 Jul). Figure 1. TRV-130 (Abmole Bioscience Inc, Houston, TX) |
| Method | chronic administration | |
| Cell Lines | mice | |
| Concentrations | 5 mg/kg twice per day on days 1-3 and on day 4, 10 mg/kg | |
| Incubation Time | 4 days | |
| Results | Figure 1A, B and the Table show that oliceridine dose–response curves were not significantly changed before and after chronic dosing (P > .05). |
 |
Source | J Psychopharmacol (2017). Figure 1. TRV130 |
| Method | injection | |
| Cell Lines | mice | |
| Concentrations | 100 nM | |
| Incubation Time | 24h | |
| Results | In the repeated-vehicle treatment group, vehicle administration on Day 4 did not produce antinociception, and mice displayed high fecal output, whereas 10 mg/kg (+)-TRV130 produced maximal antinociception in all mice and nearly maximal suppression of fecal output. In the 3-day (+)-TRV130 treatment group |
| Molecular Weight | 423.01 |
| Formula | C22H31ClN2O2S |
| CAS Number | 1401031-39-7 |
| Solubility (25°C) | DMSO ≥ 35 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Opioid Receptor Products |
|---|
| SNC162
SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. |
| ML 190
ML 190 is a selective κ opioid receptor (KOR) antagonist with an IC50 of 120 nM and an EC50 of 129 nM, respectively. |
| CCG258747
CCG258747 is a selective GRK2 inhibitor (IC50=18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, >5500, and >550–fold, respectively).CCG258747 also blocks the internalization of the µ-opioid receptor. |
| Sunobinop
Sunobinop (S 117957) is a modulator of the opioid receptor-like orphan receptor (ORL1). |
| SCH 486757
SCH 486757 is an orally effective pain peptide receptor (NOP) agonist. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
